The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Not when it comes to clinical trials it isn’t.
If you’re guaranteed a place on the trial then someone else misses out (assuming the trial has limited places).
Investors like you and I have made a pretty minimal contribution to Synairgen - the founders have been working on this for the last 15 years or so.
Appreciate your idea is probably well intentioned but you have not thought this through: imagine turning up to Tesco to do your shopping to be told you can’t because the shop is open to shareholders only?
Awful idea. Pretty much the antithesis of PR. Why should buying shares get you preferential treatment?
This is not good news but underlines why therapeutics (like SNG001 if it works as we all hope) may be important for some time to come, https://www.statnews.com/2020/09/08/astrazeneca-covid-19-vaccine-study-put-on-hold-due-to-suspected-adverse-reaction-in-participant-in-the-u-k/
So, my day went something like this:
8am-3.45pm work with short break for lunch
3.45pm Quick check of Synairgen share price - pretty relaxed because I've put what I can into Synairgen and can't add more
3.50pm hurried read of today's posts and RNS from this morning https://www.synairgen.com/wp-content/uploads/2020/09/200908-SG015-Press-Release-Final.pdf
4pm lots of swearing for not having checked email alerts earlier - apologise to dog
4.02pm wondering how anyone could read the RNS as negative?! Reading over it again in case I've missed something.
4.05pm watching RM's Proactive interview, https://www.youtube.com/watch?v=uvHGsl4KfJE - thanks for posting the link
4.15pm playing the following bit (which starts about 05:00 in) over and over again to make sure I heard the word "yet" (at 05:26):
"So we're not galloping down the COPD road right now because everything is about Covid for us. And we got some good data towards the end of July, we're really pleased with that. And we're doing exactly what we said we'd do. We're talking to regulatory agencies, and governments and other interested parties, and also focusing on manufacturing scale up. Exactly what we said. We haven't announced anything yet, so we'll just have to be a little bit patient, and hopefully we'll be able to put some good news out fairly soon."
4.20pm wondering if I'm reading too much into the "yet" and fact that RM smiles as he says it. Dog enthusiastic - possibly likes RM or thinks excitement is preparation for a walk.
4.22pm working out what other share I can sell
4.28pm buying another couple of thousand Synairgen shares before the close
MrCosts seems quite similar to macosta?
Anyway, see from 1:04 in https://m.youtube.com/watch?v=TbiqKsbkR_I
I think we should give RM a break. I imagine that, inside Synairgen, it feels like things have happened at the speed of light since Covid-19, and all the more so since the RNS of 20 July.
I've gone from checking the share price from once an hour to once a day. It doesn't really matter because I won't be selling any shares until the next significant RNS lands. I suspect there are lots of others in the same boat now.
I’m hoping that the EMA may announce a rolling review of SNG001 for the treatment of Covid-19 sometime soon - this was the process recently followed for remdesivir - see https://www.ema.europa.eu/en/news/ema-starts-rolling-review-remdesivir-covid-19
Agreed, SNG001 may only make it to county level ;o)
Re manufacturing, Synairgen has been clear on the need for the involvement of big pharma - see RM’s recent Bloomberg interview.
There are no guarantees, but hopefully SNG001 is a life changing drug, in which case this may be a life changing share.
I only visit this site occasionally. I had been wavering about whether to continue to hold, or to sell, my small holding in SNG.
The fact that Awonda appeared today has me convinced that continuing to hold is the right thing to do, even if that wasn’t his/her intention...
Sending the wrong data sets to the FDA doesn’t exactly inspire confidence, see: https://www.fiercebiotech.com/biotech/fda-spurns-cytodyn-s-hiv-drug-because-missing-info
Hope it works out for you Frank but this board is about Synairgen.
This is from around a month ago https://www.thepharmaletter.com/article/setback-for-cytodyn-as-us-fda-returns-leronlimab-submission